N9位芳基取代嘌呤-8-酮类衍生物的合成及抗肿瘤活性

合成了一系列N9位芳基取代嘌呤-8-酮类衍生物, 利用核磁共振氢谱(¹H NMR)、 核磁共振碳谱(¹³C NMR)和高分辨质谱(HRMS)进行了结构确证. 采用四甲基偶氮唑盐(MTT)法测定了目标化合物的体外抗肿瘤细胞增殖活性. 结果表明, 嘌呤酮环的C2位及N9位的取代对活性有较大影响, C2位引入对位由含氮六元环取代的苯胺, N9位引入对三氟甲基苯均有利于提高抗肿瘤活性. 化合物12c对人白血病细胞(K562)、 人前列腺癌细胞(PC-3)、 人乳腺癌细胞(MDA-MB-231)及人结肠癌细胞(HCT116)的抑制效果明显优于阳性对照药R-Roscovitine.     

新型2,6-二取代嘌呤衍生物的合成及其抗肿瘤活性

以2,6-二氯嘌呤为原料,对其2-位和6-位进行结构修饰,合成了8个新型2,6-二胺嘌呤类衍生物(3a~3h),其结构经¹H NMR, IR和MS（ESI）表征。采用MTT法研究了3a~3h对人胃癌SGC-7901细胞的体外抗肿瘤活性。结果表明: 3a, 3b, 3c, 3g具有良好的抗肿瘤活性,其中3c（IC₅₀ 65.01 μmol·L^-1）对人胃癌细胞SGC-7901的抑制作用最强。     

新型N~6-哌嗪取代腺苷衍生物的合成及其抗肿瘤活性

以腺苷为母体,对其N6-位进行结构改造,首先经邻位双羟基保护,N6-位氯代,再在N6-位引入哌嗪环制得中间体2',3'-异丙叉-6-哌嗪嘌呤核苷(4);4与N-氯乙酰苯胺类似物(6a~6h)偶联后脱除邻位双羟基保护合成了8个新型的N6-哌嗪取代腺苷衍生物(8a~8h),其结构经1H NMR,13C NMR和HR-ESI-MS表征。采用MTT法研究了8a~8h对Hela肿瘤细胞的抑制活性。结果表明:大部分目标化合物对Hela肿瘤细胞具有较好的抑制活性,其中2-{4-[9-(3,4-二羟基-5-羟甲基-四氢呋喃-2-基)-9H-嘌呤-6-基]-哌嗪-1-基}-N-(3-氟苯基)-乙酰胺(8e)的活性最好,IC50为21.74μmol·L-1。     

熊果酸衍生物的合成及抗肿瘤血管生成活性

对熊果酸C28位与C3位进行结构修饰得到了24个衍生物, 并利用 1H NMR, 13C NMR, MS及HR-MS对这些化合物进行了结构表征. 进一步通过MTT法, 以内皮细胞HUVEC为主要模型, 研究了24个衍生物抗肿瘤血管生成的活性, 同时以A549, Bel-7402及MCF-7细胞为模型研究了上述衍生物对肿瘤细胞的抑制活性. 研究结果表明, 与熊果酸相比, 化合物5, 9, 12e和14e对HUVEC细胞有较好的选择性, 化合物12a和13h比熊果酸的抗肿瘤血管生成活性略高, 因此通过适当改变熊果酸C28位的结构可以提高其对内皮细胞HUVEC的选择性, 增强抗肿瘤血管生成活性. 本文结果表明, 熊果酸及其衍生物是潜在的具有抗肿瘤血管生成作用的先导化合物, 通过有效的结构优化可能得到新型的抗肿瘤血管生成的化合物.     

N,N′-二-(3,5-二甲基苯基)-3,6-二甲基-1,4-二氢-1,2,4,5-四嗪-1,4-二甲酰胺的合成

1,2,4,5-四嗪衍生物具有抗肿瘤,杀菌,杀虫等活性,我们曾合成了具有抗肿瘤活性的N,N′-二苯基-3,6-二甲基-1,4-二氢-1,2,4,5-四嗪-1,4-二甲酰胺(3a)[1,2,3],合成路线见图1.研究它们的抗肿瘤活性时发现该化合物的苯环间位若以N,N-二甲基取代,对小鼠白血病细胞(P-388)和人肺腺癌细胞(A-549)有很强的抗肿瘤活性.     

g-C_3N_4碳位掺杂电学及光学性质的分析

使用第一性原理研究了C位掺杂的g-C3N4的电学性质和光学性质,掺杂原子为B、P、S.g-C3N4有C1位和C2位两种对称位碳原子,其中在C1位上的掺杂易于C2位,掺杂体系也较C2位稳定.相比于磷和硫在gC3N4上的掺杂,硼掺杂最易于进行.掺杂后体系的晶体结构之间差别较大,这与掺杂原子的大小以及电负性有关.由轨道布居分布可知,掺杂后的硼、磷、硫原子价电子发生了变化,表明掺杂原子发生了杂化,与相邻原子以强的共价键相连.掺杂原子与被取代的碳原子之间的价电子差异导致了能带的增加.在原来的体系中,掺杂后的体系出现了一条新的能带,因此导致实际带隙下降,表明了掺杂后的体系导电性能增强.对纯g-C3N4及掺杂g-C3N4的光学性质分析表明,g-C3N4的光学吸收主要在紫外光区,掺杂磷和硫后对g-C3N4的光吸收波长范围无改变,掺杂硼后的g-C3N4光吸收不再局限于紫外光区,而且延伸至可见光区和红外光区,并在红外光区有很强的吸收,表明g-C3N4掺杂硼后能大大地提高光催化效率.电子能量损失光谱和光导率谱以及介电常数都佐证了上述观点.     

具有生物活性的金属配合物的研究 VI: 3,6-二(二甲氨基)-二苯并碘六环镧反式-1,2-环己烷二胺四乙酸配合物的合成, 性质及抗肿瘤活性

本文在完成了[C17H20N2I][RE(EDTA)]·nH2O, [C17H20N2I]3[RE(Cit)2].nH2O及[C17H20N2I]3[RE(NTA)2].nH2O等多种配合物的合成及性质研究的基础上, 合成了3,6-二(二甲氨基)-二苯并碘六环镧反式-1,2-环己烷二胺四乙酸配合物并对其结构, 性质及抗肿瘤活性进行了研究。     

熊果酸-3’-取代丙醇酯衍生物的合成及抗肿瘤活性研究

熊果酸与1,3-二溴丙烷反应制得中间体熊果酸-3’-溴代丙醇酯(1),含溴醇酯1与含氮化合物反应,合成了系列熊果酸含氮衍生物2a～2j,均未见文献报道,其结构经1H NMR,13C NMR,IR,MS确认.初步的抗肿瘤生物活性研究表明,部分化合物的抗肿瘤活性与熊果酸相比均有提高,其中化合物2e具有更强的抑制活性.     

N1-烃基-3-肟基靛玉红的简便合成、晶体结构及抗肿瘤活性研究

研究了N1-烃基-3-肟基靛玉红的合成新方法. 以靛玉红为起始原料, 经N-烃基化、成肟反应选择性地得到单烃基化的 N1-烃基-3-肟靛玉红衍生物3a～3c. 晶体结构测定证明所合成的N1-乙基-3-肟基靛玉红(3b)以(3Z,3E)构型存在. 体外5种细胞株抗肿瘤活性筛选数据显示, 化合物3a～3c都有抗肿瘤作用, 其中, N1-乙基-3-肟基靛玉红(3b)具有较强的抗肿瘤活性和较低的毒性.     

新型7-O-(芳基氨基甲酸酯)-布雷菲德菌素A的合成及其抗肿瘤活性

芳胺与三光气反应制得芳基异氰酸酯(2a~2n);2a~2n分别对布雷菲德菌素A(3)的7-羟基进行结构修饰,合成了14个新型布雷菲德菌素A氨基甲酸酯类衍生物——7-O-(芳基氨基甲酸酯)-布雷菲德菌素A(4a~4n),其结构经1H NMR,13C NMR和ESI-HR-MS表征。初步的抗肿瘤活性测定结果表明,4i~4k均丧失抑制食管癌细胞株TE-1活性。分子对接研究揭示,引入3后,4的分子空间位阻增大,导致不能与靶位结合,致使抗肿瘤活性丧失。     

Total Synthesis of (+)‐trans‐Trikentrin A

Several syntheses have already been reported for cis‐trikentrins and herbindoles, which are indole alkaloids unsubstituted at the C2 and C3 positions that bear a trans‐1,3‐dimethylcyclopentyl unit. Herein, we describe the first asymmetric and stereoselective synthesis of the more challenging trans‐trikentrin A as its naturally occurring isomer. Different approaches were investigated and the strategy of choice was a combination of an enzymatic kinetic resolution and a thallium(III)‐mediated ring contraction. The antiproliferative activities of the natural product and related intermediates have been tested against human tumor cell lines, leading to the discovery of new compounds with potent antitumor activity.     

Novel synthetic acridine-based derivatives as topoisomerase Ⅰ inhibitors

Novel DNA binding agents against topoisomerases are needed for effective treatment of cancers. A series of new acridine-based derivatives 7a–7d were synthesized and their antiproliferative activity against K562 and HepG-2 cell lines were evaluated. Compound 7c with pyridin-2-yl-methanamino group substituted at the C9 position of acridine showed good antitumor activity against both cell lines. The DNA-binding affinity of compound 7c was evaluated by UV–vis absorption spectra and fluorescence emission spectra. DNA topoisomerase I mediated relaxation of plasmid pBR322 DNA was also tested. Our results suggested that compound 7c with good antitumor activity and topoisomerase I inhibition activity can be developed as a prime candidate for further chemical optimization.     

Design and Synthesis of Hydrazine and Oxadiazole-containing Derivatives of Sorafenib as Antitumor Agents

A series of hydrazine and oxadiazole analogs of Sorafenib was designed, synthesized and characterized by proton nuclear magnetic resonance(¹H NMR) spectrometry and high resolution mass spectrometry(HRMS). The antiproliferative activities of these compounds against human colorectal carcinoma(HCT-116) and human breast cancer (MDA-MB-231) tumor cell lines were evaluated in vitro by MTT method[MTT=3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide]. The bioassay results suggest that most of the synthesized compounds have antitumor potential to HCT-116 cell line compared with MDA-MB-231 cell line. Compounds 8a,8b,8d, 8e,9f and 9j competitive with Sorafenib demonstrated antiproliferative activities on HCT-116 cell line.     

Synthesis and biological activities of lipid A analogs: modification of a glycosidically bound group with chemically stable polar acidic groups and lipophilic groups on the disaccharide backbone with tetradecanoyl or N-dodecanoylglycyl groups.

Six novel lipid A analogs were synthesized. The first two analogs, 4 and 5, have an alpha-glycosidically bound carboxymethyl or 1,3-dicarboxyisopropyl group on the disaccharide backbone with four tetradecanoyl groups. The next three analogs, 6, 7 and 8, have two or four N-dodecanoylglycyl groups on the 1-alpha-O-phosphonooxyethylated disaccharide backbone. Analog 6 bears N-dodecanoylglycyl groups on the hydroxyl functions at positions 3 and 3', and tetradecanoyl groups on the amino functions at positions 2 and 2'. Analog 7 is a 2, 3, 2' and 3'-tetrakis(N-dodecanoylglycyl) derivative, and analog 8 resembles compound 6, but the binding of the N-dodecanoylglycyl and tetradecanoyl groups at positions 2, 2' and 3, 3' are reversed. The third analog, 9, has the same acyl group configuration as compound 6, but has a 1,3-dicarboxyisopropyl group at position C-1. Compounds 4 and 5 exhibited definite antitumor activity against Meth A fibrosarcoma, indicating that the phosphate group at the C-1 position in lipid A could be replaced by the carboxylic acid without reducing the antitumor activity. In rabbits, compounds 6 and 9 exhibited potent antitumor activity, but their toxicity was extremely low. On the other hand, compounds 7 and 8 showed no antitumor activity. The levels of antitumor activity of 6 and 9 were similar to those of the natural-type lipid A. The antitumor activities of analogs with a N-dodecanoylglycyl group on the disaccharide backbone depended on the connecting sites of the acyl groups.     

Factor analysis of in vitro antitumor activities of platinum complexes

Factor analysis was applied to the data matrix of in vitro growth inhibitory activities of 52 platinum complexes against 9 tumor cell lines, L1210, P388, Lewis lung, AH66, AH66F, HeLa S3, KB, HT-1197 and HT-1376 cell lines. Three factors were obtained by the principal factor analysis method. After the varimax rotation of these three factors, tumor cell lines were classified into four groups according to their factor loadings. The platinum complexes were characterized by the factor scores. Cisplatin was situated in an extreme position as compared with the other platinum complexes. In vivo antitumor activities of the platinum complexes were tested against L1210 and LL murine tumor models. The in vivo activity against L1210 showed a negative correlation with that against LL. Factor 2 scores of the complexes obtained by factor analysis of in vitro antitumor activities showed a good correlation with these in vivo antitumor activities. Then, the structure-factor 2 score relationships among platinum complexes were analyzed by the Free-Wilson method. From this analysis, structure-activity relationships for carrier ligands and leaving groups are proposed. Factor analysis is suggested to be a useful method to establish an efficient screening system for platinum complexes.     

Effects of Vanadyl Complexes with Acetylacetonate Derivatives on Non-Tumor and Tumor Cell Lines

Vanadium has a good therapeutic potential, as several biological effects, but few side effects, have been demonstrated. Evidence suggests that vanadium compounds could represent a new class of non-platinum, metal antitumor agents. In the present study, we aimed to characterize the antiproliferative activities of fluorescent vanadyl complexes with acetylacetonate derivates bearing asymmetric substitutions on the β-dicarbonyl moiety on different cell lines. The effects of fluorescent vanadyl complexes on proliferation and cell cycle modulation in different cell lines were detected by ATP content using the CellTiter-Glo Luminescent Assay and flow cytometry, respectively. Western blotting was performed to assess the modulation of mitogen-activated protein kinases (MAPKs) and relevant proteins. Confocal microscopy revealed that complexes were mainly localized in the cytoplasm, with a diffuse distribution, as in podocyte or a more aggregate conformation, as in the other cell lines. The effects of complexes on cell cycle were studied by cytofluorimetry and Western blot analysis, suggesting that the inhibition of proliferation could be correlated with a block in the G2/M phase of cell cycle and an increase in cdc2 phosphorylation. Complexes modulated mitogen-activated protein kinases (MAPKs) activation in a cell-dependent manner, but MAPK modulation can only partly explain the antiproliferative activity of these complexes. All together our results demonstrate that antiproliferative effects mediated by these compounds are cell type-dependent and involve the cdc2 and MAPKs pathway.     

Design,Synthesis and Antiproliferative Activities of Diaryl Thiourea Derivatives as Anticancer Agents

Two new series of diaryl thiourea containing sorafenib derivatives 9a – 9t were designed and synthesized, and their antiproliferative activities against PC‐3, HCT116 and MDA‐MB‐231 cell lines were evaluated. All compounds generally showed antiproliferative activity to PC‐3 cells, most of the analogs exhibited potent antiproliferative activity to HCT116 cells, and compounds 9e , 9f , 9o and 9p demonstrated inhibitory activities against all three cell lines. The structures of all the newly synthesized compounds were determined by ¹H NMR, ¹³C NMR and HRMS.     

The mechanism of selective purine C-nitration revealed: NMR studies demonstrate formation and radical rearrangement of an N7-nitramine intermediate

Modified purine derivatives are of great importance in biomedical sciences, and substitution reactions on the purine skeleton are intensively studied. In our laboratory, an efficient and selective purine C2-nitration reaction was developed using a mixture of tetrabutylammonium nitrate and trifluoroacetic anhydride. The resulting 2-nitro moiety appeared to be a versatile handle to introduce a variety of pharmacophores onto the purine skeleton. Since the mechanism of this selective purine C2-nitration reaction has remained unclear, we now present an extensive NMR study leading to its elucidation, using N9-Boc-protected 6-chloropurine as a model compound. Direct electrophilic aromatic nitration of the highly electron-deficient C2 position was excluded, and we demonstrate that this reaction occurs in a three-step process. Electrophilic attack by trifluoroacetyl nitrate on the purine N7 position results in a nitrammonium species that is trapped by a trifluoroacetate anion furnishing N7-nitramine intermediate 11. This intermediate was characterized at -50 degrees C by (1)H, (13)C, (15)N, and (19)F NMR. At T > -40 degrees C, the N7-nitramine intermediate undergoes a nitramine rearrangement, which generates a C2-nitro species that immediately eliminates TFA to give 2-nitro-6-chloro-9-Boc purine 10. The involvement of radicals during the nitramine rearrangement was unequivocally established by (15)N-CIDNP. Moreover, the emission signal observed for the rearranged product, 2-nitropurine 10, showed that it is primarily formed in an intermolecular process. A quantitative radical trapping experiment finally disclosed that 65-70% of the nitramine rearrangement takes place intermolecularly.     

新型1,3-二取代酞嗪酮类衍生物的合成及抗肿瘤活性研究

为了寻找高效低毒的抗肿瘤药物,设计并合成新型的1,3位取代酞嗪酮类化合物.采用噻唑蓝(MTT)法对目标化合物在MCF-7(人乳腺癌细胞)、PC-3(人前列腺癌细胞)、SW-620(人结肠癌细胞)和HGC-27(人胃癌细胞)四种人类癌细胞的抗增殖活性进行评价.结果显示大部分化合物具有较好的抗增殖活性.其中,2-(4-(4-溴苯基)-1-氧代酞嗪-2(1H)-基)-N-(2-氟苯基)乙酰胺(5g)对MCF-7细胞的抗增殖活性较好,IC50值为6.01μmol/L,为抗肿瘤药物的研究提供了思路.